RESUMEN
The landscape of human memory and event cognition research has witnessed a transformative journey toward the use of naturalistic contexts and tasks. In this review, we track this progression from abrupt, artificial stimuli used in extensively controlled laboratory experiments to more naturalistic tasks and stimuli that present a more faithful representation of the real world. We argue that in order to improve ecological validity, naturalistic study designs must consider the complexity of the cognitive phenomenon being studied. Then, we review the current state of "naturalistic" event segmentation studies and critically assess frequently employed movie stimuli. We evaluate recently developed tools like lifelogging and other extended reality technologies to help address the challenges we identified with existing naturalistic approaches. We conclude by offering some guidelines that can be used to design ecologically valid cognitive neuroscience studies of memory and event cognition.
RESUMEN
Post-COVID-19 conditions (long COVID) has impacted many individuals, yet risk factors for this condition are poorly understood. This retrospective analysis of 88,943 COVID-19 patients at a multi-state US health system compares phenotypes, laboratory tests, medication orders, and outcomes for 1,086 long-COVID patients and their matched controls. We found that history of chronic pulmonary disease (CPD) (odds ratio: 1.9, 95% CI: [1.5, 2.6]), migraine (OR: 2.2, [1.6, 3.1]), and fibromyalgia (OR: 2.3, [1.3, 3.8]) were more common for long-COVID patients. During the acute infection phase long COVID patients exhibited high triglycerides, low HDL cholesterol, and a high neutrophil-lymphocyte ratio; and were more likely hospitalized (5% vs. 1%). Our findings suggest severity of acute infection and history of CPD, migraine, chronic fatigue syndrome (CFS), or fibromyalgia as risk factors for long COVID. These results suggest that suppressing acute disease severity proactively, especially in patients at high risk, can reduce incidence of long COVID.
RESUMEN
Anthropogenic activities have negatively impacted the ecosystem dramatically over the last few decades. The environment is becoming more contaminated with heavy metals, pesticides, and microplastics (MPs) as a result of the swift rise in industrialization and urbanisation. These contaminants are present everywhere in the ecosystem, affecting every living creature, from aquatic to terrestrial to aerial. Recently, the widespread of microplastics in the environment has raised serious concerns about the contamination of honey bees by these tiny particles of plastic. Honeybees are the major pollinators which contributes in the pollination of about 70% food that we consume. This review summarizes current research findings on the presence, uptake, and possible effects of microplastics on honey bees. Findings revealed the presence of microplastics in various honey bee matrices, such as honey, pollen, beeswax, and bee bodies, highlighting the potential routes of exposure for these vital pollinators. Additionally, evidence suggests that microplastics can accumulate in honey bee tissues (brain, midgut, Malpighian tubules, trachea, and haemolymph) potentially leading to adverse effects on honey bee health, behaviour, and colony dynamics. Additionally, MPs has a synergistic impact on immune system as well. Change in cuticle profile, reduction in body weight, and changes in eating frequency can regulate overall success rate of their survival. However, significant knowledge gaps remain regarding the long-term consequences for honey bee populations and ecosystem health, which cannot unveil the ultimate degree of future threats. Future research efforts should focus on investigating the interactions between microplastics and other stressors, such as pesticides and pathogens, and assessing the broader ecological implications of honey bee contamination with microplastics. Addressing these knowledge gaps is essential for developing effective mitigation strategies to minimize the impact of microplastics on honey bee populations and safeguarding their vital role in ecosystem functioning and food security.
RESUMEN
Human T-cell leukemia virus type 1 (HTLV-1) can cause HTLV-1 Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP). Current treatment options for HAM/TSP are limited. We present a woman with rapidly-progressive HAM/TSP with significant, sustained clinical improvement following initiation of mycophenolate mofetil (MMA). Peripheral blood mononuclear cells from the patient, her asymptomatic carrier husband and eight healthy controls were isolated. Frequencies of T-cell populations upon exposure to low and high MMA concentrations and differences in proliferation were analyzed using flow cytometry and a CSFE-proliferation assay. Characterization of T-cell function and proliferation showed higher levels of GranzymeB in HTLV-1+ donors. The improvement and stability of symptoms in this patient with HAM/TSP following MMA initiation requires further study as a potential treatment for HAM/TSP.
Asunto(s)
Virus Linfotrópico T Tipo 1 Humano , Paraparesia Espástica Tropical , Humanos , Femenino , Virus Linfotrópico T Tipo 1 Humano/fisiología , Ácido Micofenólico/uso terapéutico , Leucocitos Mononucleares , Paraparesia Espástica Tropical/tratamiento farmacológico , Paraparesia Espástica Tropical/diagnósticoRESUMEN
Peptides are increasingly important drug candidates, offering numerous advantages over conventional small molecules. However, they face significant challenges related to stability, cellular uptake and overall bioavailability. While individual modifications may not address all these challenges, macrocyclisation stands out as a single modification capable of enhancing affinity, selectivity, proteolytic stability and membrane permeability. The recent successes of in situ peptide modifications during screening in combination with genetically encoded peptide libraries have increased the demand for peptide macrocyclisation reactions that can occur under biocompatible conditions. In this perspective, we aim to distinguish biocompatible conditions from those well-known examples that are fully bioorthogonal. We introduce key strategies for biocompatible peptide macrocyclisation and contextualise them within contemporary screening methods, providing an overview of available transformations.